BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33196628)

  • 1. The Problem of Subclinical Antibody-mediated Rejection in Kidney Transplantation.
    Filippone EJ; Farber JL
    Transplantation; 2021 Jun; 105(6):1176-1187. PubMed ID: 33196628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study.
    Bertrand D; Gatault P; Jauréguy M; Garrouste C; Sayegh J; Bouvier N; Caillard S; Lanfranco L; Galinier A; Laurent C; Etienne I; Farce F; François A; Guerrot D
    Transplantation; 2020 Aug; 104(8):1726-1737. PubMed ID: 32732853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies.
    Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D
    Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Impact of Delayed Graft Function in Deceased Donor Renal Transplant Recipients With and Without Donor-specific HLA-antibodies.
    Haller J; Wehmeier C; Hönger G; Hirt-Minkowski P; Gürke L; Wolff T; Steiger J; Amico P; Dickenmann M; Schaub S
    Transplantation; 2019 Sep; 103(9):e273-e280. PubMed ID: 31205266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation.
    Rao S; Ghanta M; Lee IJ; Gillespie A; Parekh HK; Geier SS; Zeng X; Karachristos A; Lau KN; Karhadkar S; Di Carlo A; Sifontis NM; Constantinescu S
    Clin Transpl; 2014; ():143-51. PubMed ID: 26281139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summary of 2017 FDA Public Workshop: Antibody-mediated Rejection in Kidney Transplantation.
    Velidedeoglu E; Cavaillé-Coll MW; Bala S; Belen OA; Wang Y; Albrecht R
    Transplantation; 2018 Jun; 102(6):e257-e264. PubMed ID: 29470345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
    Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
    Yamamoto T; Watarai Y; Takeda A; Tsujita M; Hiramitsu T; Goto N; Narumi S; Katayama A; Morozumi K; Uchida K; Kobayashi T
    Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
    Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
    Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rejection of the Renal Allograft in the Absence of Demonstrable Antibody and Complement.
    Zhao X; Huang G; Randhawa S; Zeng G; Lunz J; Randhawa P
    Transplantation; 2017 Feb; 101(2):395-401. PubMed ID: 26901079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
    Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
    Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
    Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
    Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
    Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
    Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
    Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
    Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation.
    Parajuli S; Redfield RR; Garg N; Aziz F; Mohamed M; Astor BC; Zhong W; Djamali A; Mandelbrot DA
    Transplantation; 2019 Jul; 103(7):1468-1476. PubMed ID: 30335696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.